Correctly folded etanercept in high purity and excellent yield
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.
1. A stable aqueous etanercept-containing pharmaceutical composition comprising:
a) an etanercept-containing protein mixture comprising correctly folded etanercept in an amount constituting greater than 95 wt % of the protein mixture and less than 5 wt % incorrectly folded etanercept, wherein said incorrectly folded etanercept is an etanercept protein that has a conformation different from that of the correctly folded etanercept and said different conformation renders said incorrectly folded etanercept protein lacking in biological activity as a TNF inhibitor and said incorrectly folded etanercept is not an aggregate, wherein said etanercept-containing protein mixture is obtained by a mixed-mode chromatography procedure comprising binding correctly folded etanercept and incorrectly folded etanercept to a mixed-mode chromatography resin having both ion exchange and hydrophobic moieties and contacting the mixed-mode chromatography resin to elute with a salt solution at a pH between 4.5 and 8.5;
b) about 0.1 to 2 weight percent of a correctly folded etanercept-stabilizing combination of sucrose, sodium citrate, and one of alanine, glycine, and lysine;
c) 0 to about 25 mM sodium chloride;
d) a buffer selected from phosphate, histidine, citrate, maleate, tartrate, acetate, tris-(hydroxymethyl)-aminomethane (tris), and bicarbonate, or a combination thereof,
wherein the composition does not contain cysteine and does not contain arginine,
wherein the composition is an aqueous pharmaceutical composition having a pH of about 6.2 to 7.4.
2. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein the correctly folded etanercept-stabilizing combination contains sucrose, sodium citrate, and alanine.
3. The stable aqueous etanercept-containing pharmaceutical composition of claim 2 , comprising about 25 mM sodium chloride.
4. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein the correctly folded etanercept-stabilizing combination contains sucrose, sodium citrate, and glycine.
5. The stable aqueous etanercept-containing pharmaceutical composition of claim 4 , comprising about mM sodium chloride.
6. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein the correctly folded etanercept-stabilizing combination contains sucrose, sodium citrate, and lysine.
7. The stable aqueous etanercept-containing pharmaceutical composition of claim 6 , comprising about 25 mM sodium chloride.
8. The stable aqueous etanercept-containing pharmaceutical composition of claim 7 , wherein the composition does not contain any amino acid other than lysine.
9. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein less than 3 wt % of the etanercept in the etanercept-containing protein mixture is incorrectly folded etanercept.
10. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein less than 1 wt % of the etanercept in the etanercept-containing protein mixture is incorrectly folded etanercept.
11. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein at least 98 wt % of the etanercept in the etanercept-containing protein mixture is correctly folded etanercept.
12. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein the aqueous buffer is citrate buffer.
13. The stable aqueous etanercept-containing pharmaceutical composition of claim 1 , wherein the stable aqueous etanercept-containing pharmaceutical composition comprises less than 3 wt % aggregates of correctly folded etanercept.
14. A vial, syringe, or injector pen containing the stable aqueous etanercept-containing pharmaceutical composition of claim 8 .
15. A vial, syringe, or injector pen containing the stable aqueous etanercept-containing pharmaceutical composition of claim 12 .
16. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the stable aqueous etanercept-containing pharmaceutical composition according to claim 1 .
17. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the stable aqueous etanercept-containing pharmaceutical composition according to claim 10 .
18. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the stable aqueous etanercept-containing pharmaceutical composition according to claim 11 .
19. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the stable aqueous etanercept-containing pharmaceutical composition according to claim 3 .
20. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the stable aqueous etanercept-containing pharmaceutical composition according to claim 5 .
21. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the stable aqueous etanercept-containing pharmaceutical composition according to claim 12 .